Citadel Advisors’s Emergent Biosolutions EBS Stock Holding History

Citadel Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$451K	Sell	54,300 -19,000	-26%	-$197K	﹤0.01%	9550
2025 Q4	$906K	Sell	73,300 -13,100	-15%	-$140K	﹤0.01%	7614
2025 Q3	$762K	Buy	86,400 +23,400	+37%	+$182K	﹤0.01%	8147
2025 Q2	$402K	Sell	63,000 -22,200	-26%	-$127K	﹤0.01%	9133
2025 Q1	$414K	Sell	85,200 -19,800	-19%	-$164K	﹤0.01%	8895
2024 Q4	$1M	Sell	105,000 -66,400	-39%	-$609K	﹤0.01%	7006
2024 Q3	$1.43M	Buy	171,400 +30,700	+22%	+$279K	﹤0.01%	6150
2024 Q2	$960K	Buy	140,700 +79,800	+131%	+$343K	﹤0.01%	6668
2024 Q1	$154K	Buy	60,900 +5,400	+10%	+$12.2K	﹤0.01%	10725
2023 Q4	$133K	Sell	55,500 -23,300	-30%	-$54.8K	﹤0.01%	10576
2023 Q3	$268K	Buy	78,800 +37,600	+91%	+$208K	﹤0.01%	9356
2023 Q2	$303K	Sell	41,200 -38,700	-48%	-$359K	﹤0.01%	9030
2023 Q1	$828K	Buy	79,900 +66,400	+492%	+$803K	﹤0.01%	7206
2022 Q4	$159K	Sell	13,500 -10,400	-44%	-$161K	﹤0.01%	10511
2022 Q3	$502K	Buy	23,900 +4,900	+26%	+$136K	﹤0.01%	8442
2022 Q2	$590K	Buy	19,000 +400	+2%	+$13.7K	﹤0.01%	8269
2022 Q1	$764K	Sell	18,600 -11,900	-39%	-$525K	﹤0.01%	8344
2021 Q4	$1.33M	Sell	30,500 -6,700	-18%	-$303K	﹤0.01%	7191
2021 Q3	$1.86M	Sell	37,200 -31,600	-46%	-$1.91M	﹤0.01%	6546
2021 Q2	$4.33M	Buy	68,800 +26,000	+61%	+$1.67M	﹤0.01%	4745
2021 Q1	$3.98M	Buy	42,800 +9,600	+29%	+$983K	﹤0.01%	4769
2020 Q4	$2.98M	Buy	33,200 +11,300	+52%	+$1.04M	﹤0.01%	4595
2020 Q3	$2.26M	Buy	21,900 +5,000	+30%	+$539K	﹤0.01%	4496
2020 Q2	$1.34M	Buy	16,900 +5,900	+54%	+$440K	﹤0.01%	5299
2020 Q1	$636K	Buy	11,000 +7,100	+182%	+$409K	﹤0.01%	6090
2019 Q4	$210K	Sell	3,900 -5,600	-59%	-$304K	﹤0.01%	8100
2019 Q3	$497K	Buy	+9,500	New	+$443K	﹤0.01%	6760
2019 Q2	–	Sell	-9,100	Closed	-$460K	–	9297
2019 Q1	$460K	Buy	9,100 +4,100	+82%	+$242K	﹤0.01%	6927
2018 Q4	$296K	Buy	5,000 +1,800	+56%	+$116K	﹤0.01%	7297
2018 Q3	$211K	Buy	+3,200	New	+$187K	﹤0.01%	8139
2018 Q1	–	Sell	-6,900	Closed	-$321K	–	8368
2017 Q4	$321K	Buy	+6,900	New	+$290K	﹤0.01%	6352
2017 Q1	–	Sell	-10,900	Closed	-$358K	–	7550
2016 Q4	$358K	Buy	+10,900	New	+$327K	﹤0.01%	5419
2016 Q3	–	Sell	-52,500	Closed	-$1.48M	–	7329
2016 Q2	$1.48M	Buy	52,500 +26,000	+98%	+$1.02M	﹤0.01%	3076
2016 Q1	$963K	Sell	26,500 -4,500	-15%	-$159K	﹤0.01%	3538
2015 Q4	$1.24M	Buy	31,000 +8,300	+37%	+$289K	﹤0.01%	3312
2015 Q3	$647K	Buy	22,700 +12,700	+127%	+$418K	﹤0.01%	4424
2015 Q2	$330K	Buy	10,000 +3,400	+52%	+$105K	﹤0.01%	5613
2015 Q1	$190K	Buy	+6,600	New	+$189K	﹤0.01%	6235
2014 Q3	–	Sell	-2,000	Closed	-$45K	–	8173
2014 Q2	$45K	Buy	+2,000	New	+$46.6K	﹤0.01%	6814

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's EBS Position: Q1 2026 in Review

Citadel Advisors sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 232,019 shares — an estimated $2.4M sold.

Citadel Advisors first reported a position in EBS in Q2 2013 and held it in 51 quarters. The position peaked at $12.1M in Q3 2022. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

Citadel Advisors reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 232,019 Emergent Biosolutions shares in Q1 2026, an estimated $2.4M.
Citadel Advisors first reported a position in Emergent Biosolutions in Q2 2013 and held it in 51 quarters.
Citadel Advisors's Emergent Biosolutions position peaked at $12.1M in Q3 2022.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.